drugset / Trial / NCT00865215

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

NCT00865215

Phase 1 Completed 60 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is TO compare the relative bioavailability of Propranolol Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg Capsules (Wyeth Pharmaceuticals) following a single oral dose (1 x 160 mg) in healthy adult volunteers under fasting conditions.

Timeline

Start
2005-04
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 160 mg Oral

Indications

No indication recorded.